Use of an Automated Insulin Delivery System Compared to Sensor Augmented Pump at Patients With Type 1 Diabetes (T1D) (DREAM5)

Open-label, 3 Center, Randomized, Cross-over Study to Evaluate the Safety and Efficacy of 60 Hours Closed-loop Control Using the MD-Logic Automated Insulin Delivery System Compared to Sensor Augmented Pump Therapy at T1D Patients at Home

Title: An open-label, three-center, randomized, cross-over study to evaluate the safety and efficacy of day and night closed-loop control using the MD-Logic automated insulin delivery system compared to sensor augmented pump therapy at patients with type 1 diabetes at home Indication: Type 1 Diabetes mellitus using an insulin pump therapy and continues glucose sensors The objective of this pilot study is to evaluate the safety and efficacy of 60 hours blood glucose control, using the MD-Logic System in individuals with type 1 diabetes at patient's home.

The duration of study participation for one subject is 28-56 days and the overall duration of the study is 6 months The participants of the study are patients ≥ 10 years until 65 years with Type 1 Diabetes mellitus using and insulin pump therapy and continuous glucose sensors.

Sample Size n = 45

Study Overview

• Status: Completed
• Conditions: Type 1 Diabetes
• Intervention / Treatment: Device: MD-Logic-Automated Insulin Delivery System; Device: MiniMed Paradigm® Veo™ System

Detailed Description

Up to 45 eligible patients will be enrolled to participate in two crossover sessions of 60 hours of consecutive days, with closed-loop or sensor-augmented pump therapy (Minimed ®Paradigm). The sequence of the sessions will be randomly assigned. The randomization will be blocked randomization (1:1). Patients will be assigned to one of the following arm: Group A: 60 hours under closed-loop control and then 60 hours of sensor augmented pump therapy and Group B: 60 hours using sensor augmented pump therapy and then 60 hours under closed-loop control.

Subjects will be enrolled according to the following schedule/ successive phases:

Phase 1: 5 Adult subjects: After all adult subjects have completed the study the 2nd enrollment phase starts.

Phase 2: 5 Adolescent subjects aged 14-18. After these subjects have completed the study the 3rd enrollment phase starts.

Phase 3: 5 Children aged 10-14 will be enrolled.

The enrollment of phase 2 and phase 3 will not be started before all participants of the previous phase completed the study and the safety and efficacy of the system has been analyzed based on the occurrence of (serious) adverse Events (AE) or any other issue relevant for patient's safety. If the observed AEs or device problems do not exceed the amount or severity of the risks expected during a regular diabetes therapy and the recruitment of the next age category is considered reasonable from the medical point of view, the next enrollment phase will be started.Screening Failures will be replaced to get a total of 45 completed patients.The average duration of study participation for subjects completing the study is estimated to be approximately 28-56 days. The estimated duration of the total study is 6 months.In this study 45 patients will be included, 15 are planned to be enrolled in Germany.

The study will consist of 5 visits (3 clinical visits and 2 visits will be done by phone) as followed:

• Visit 1: Screening, eligibility, enrolment and sensor and diabetes guidelines training. (Day - 21)
• Run-in period
• Visit 2: Randomization and preparation visit for the outpatient period. (Day 0)
• Intervention session 1 (same weekdays as Intervention session 2)
• Visit 3: Phone call visit between arms. (Day 4)
• Washout period
• Visit 4: Phone call visit before session 2 (Day 18)
• Intervention session 2 (same weekdays as Intervention session 1)
• Visit 5: Final visit. (Day 21)

There is no follow up visit or observation planned after the end of the study or after a subject discontinued study participation. In case of a Serious Adverse Event (SAE) a follow up period until this SAE is resolved/ recovered is planned.

• Study Type: Interventional
• Enrollment (Actual): 45
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Germany
  • Hannover, Germany, 30173
    • Kinder - und Jugendkrankenhaus AUF DER BULT

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 10 years to 65 years (Child, Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Subject with Type 1 diabetes (>1yr since diagnosis)
2. Insulin infusion pump (CSII) therapy for at least 3 months
3. Patients using a Continuous glucose monitoring system
4. Age ≥ 10 years until 65 years
5. HbA1c at inclusion ≥ 7 and <10
6. Patients willing to follow study instructions
7. Patients live with at least one other adult person
8. BMI SDS (Standard Deviation Scores) - below the 95th percentile for age32
9. Patients with care givers who are capable of operating a computer based system.

Exclusion Criteria:

1. Concomitant diseases that influence metabolic control (e.g. anemia, significantly impaired hepatic function, renal failure, History of adrenal insufficiency) or other medical condition, which in the Investigator's opinion, may compromise patient safety as the following examples:

   • Abnormal liver or renal function (Transaminase >2 times the upper limit of normal, Creatinine > 1.5 mg/dL)
   • Subject has had any of the following diagnoses within 1 year of screening: myocardial infarction, unstable angina, coronary artery disease or congestive heart failure, coronary artery surgery, transient ischemic attack, cerebrovascular accident, uncontrolled hypertension, ventricular rhythm disturbances or thromboembolic disease Note: Adequately treated thyroid disease and celiac disease do not exclude subjects from enrollment
2. Participation in any other interventional study
3. Known or suspected allergy to trial products such as adhesives, tapes, needles. An allergy to contrast medium, use of other active medical devices (such as pacemaker, ICD) and planned imaging examinations (such as MRI).
4. Any significant diseases or conditions including psychiatric disorders and substance abuse that, in the opinion of the investigator, is likely to affect the subject's ability to complete the study, or compromise patient safety
5. Diabetic ketoacidosis in the past 1 month.
6. Severe hypoglycemia six month prior to enrollment.
7. Current use of the following medications: medications that are used to lower blood glucose such as Pramilintide, Metformin and GLP-1 (Glucagon-like Peptide-1) analogs. Beta blockers, glucocorticoids and other medications, which in the judgment of the investigator would be a contraindication to participation in the study
8. Subject is participating in another drug or device study that could affect glucose measurements or glucose management.
9. Female subject who is pregnant or breast-feeding or is planning to become pregnant within the planned study duration.
10. Not sufficient vision or hearing to recognize pump/ sensor alarms or to perform blood glucose -self measurements 4-times daily.

11. Relevant severe organ disorders (diabetic nephropathy, diabetic retinopathy, , diabetic foot syndrome) or any secondary disease or complication of diabetes mellitus

    • Subject has unstable or rapidly progressive renal disease or is receiving dialysis
    • Subject has active proliferating retinopathy
    • Active gastroparesis
12. Patient suffers from an eating disorder

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: investigational device; MD-Logic-Automated Insulin Delivery System, Version 01.05.02 The device is being used continuously over 60 hours for insulin therapy	Device: MD-Logic-Automated Insulin Delivery System; Subjects will undergo 60 hours at home under MD-Logic control and continuing with their regular routine life. At evening of the first intervention day patients will switch to MD-Logic control. Patients will be asked to connect study sensor and pump to the computer using the MD-Logic software. After the activation of the MD-Logic system, basal insulin dosing and correction boluses will be fully automated and controlled by the MD-Logic system except to meal boluses. Patients will be encouraged to measure capillary blood glucose at least 4 times a day, before each meal and before bed time. After the third night the patient will turn the closed-loop controller "OFF", this will automatically save the log file. The patient will return to his regular insulin treatment.; Other Names: Closed loop
Placebo Comparator: MiniMed Paradigm® Veo™ System; sensor augmented insulin pump The device is being used continuously over 60 hours for insulin therapy	Device: MiniMed Paradigm® Veo™ System; Subjects use 60 hours at home their conventional insulin pump and continuing with their regular Routine life. During this therapy the Insulin pump operating separately and are not controlled by the MD-Logic System.; Other Names: sensor augmented continuous subcutaneous insulin infusion

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
normal glucose level	Percentage of Glucose sensor readings within 70 to 180mg/dl (3.9 to 10 mmol/l)	60 hours

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Hypoglycemia	Percentage of glucose sensor readings below 70 mg/dl (3.9 mmol/l)	60 hours
increased glucose level	Percentage of glucose sensor readings above 180mg/dl (10 mmol/l)	60 hours
glucose sensor readings	Average and Standard deviation of glucose sensor readings	90 hours

Collaborators and Investigators

• Sponsor: Kinderkrankenhaus auf der Bult
• Investigators: Principal Investigator: Thomas Danne, MD, Kinder- und Jugendkrankenhaus Auf der Bult

Study record dates

Study Major Dates

• Study Start: December 1, 2015
• Primary Completion (Actual): June 1, 2016
• Study Completion (Actual): June 1, 2016

Study Registration Dates

• First Submitted: December 17, 2015
• First Submitted That Met QC Criteria: December 18, 2015
• First Posted (Estimate): December 21, 2015

Study Record Updates

• Last Update Posted (Actual): February 28, 2018
• Last Update Submitted That Met QC Criteria: February 27, 2018
• Last Verified: February 1, 2018

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Glucose Metabolism Disorders; Metabolic Diseases; Immune System Diseases; Autoimmune Diseases; Endocrine System Diseases; Diabetes Mellitus; Diabetes Mellitus, Type 1; Hypoglycemic Agents; Physiological Effects of Drugs; Insulin; Insulin, Globin Zinc
• Other Study ID Numbers: MC-01

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No